vs
安朗杰（ALLE）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
安朗杰的季度营收约是Medpace Holdings, Inc.的1.5倍（$1.0B vs $708.5M）。Medpace Holdings, Inc.净利率更高（19.1% vs 14.3%，领先4.8%）。Medpace Holdings, Inc.同比增速更快（32.0% vs 9.3%）。安朗杰自由现金流更多（$200.5M vs $188.1M）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 7.5%）
安朗杰是全球知名的安防产品及解决方案供应商，面向全球生产销售机械与电子类安防产品，包括闭门器、出入口控制设备、锁具、电子门禁系统、考勤与人员效能管理系统、门体系统及相关配件，服务商业、公共机构、住宅等多领域终端用户
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
ALLE vs MEDP — 直观对比
营收规模更大
ALLE
是对方的1.5倍
$708.5M
营收增速更快
MEDP
高出22.8%
9.3%
净利率更高
MEDP
高出4.8%
14.3%
自由现金流更多
ALLE
多$12.4M
$188.1M
两年增速更快
MEDP
近两年复合增速
7.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $708.5M |
| 净利润 | $147.5M | $135.1M |
| 毛利率 | 44.5% | — |
| 营业利润率 | 20.3% | 21.6% |
| 净利率 | 14.3% | 19.1% |
| 营收同比 | 9.3% | 32.0% |
| 净利润同比 | 2.4% | 15.5% |
| 每股收益（稀释后） | $1.70 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALLEMEDP
| Q4 25 | $1.0B | $708.5M | ||
| Q3 25 | $1.1B | $659.9M | ||
| Q2 25 | $1.0B | $603.3M | ||
| Q1 25 | $941.9M | $558.6M | ||
| Q4 24 | $945.6M | $536.6M | ||
| Q3 24 | $967.1M | $533.3M | ||
| Q2 24 | $965.6M | $528.1M | ||
| Q1 24 | $893.9M | $511.0M |
净利润ALLEMEDP
| Q4 25 | $147.5M | $135.1M | ||
| Q3 25 | $188.4M | $111.1M | ||
| Q2 25 | $159.7M | $90.3M | ||
| Q1 25 | $148.2M | $114.6M | ||
| Q4 24 | $144.1M | $117.0M | ||
| Q3 24 | $174.2M | $96.4M | ||
| Q2 24 | $155.4M | $88.4M | ||
| Q1 24 | $123.8M | $102.6M |
毛利率ALLEMEDP
| Q4 25 | 44.5% | — | ||
| Q3 25 | 45.8% | — | ||
| Q2 25 | 45.6% | — | ||
| Q1 25 | 44.9% | — | ||
| Q4 24 | 44.1% | — | ||
| Q3 24 | 44.7% | — | ||
| Q2 24 | 44.4% | — | ||
| Q1 24 | 43.8% | — |
营业利润率ALLEMEDP
| Q4 25 | 20.3% | 21.6% | ||
| Q3 25 | 21.8% | 21.5% | ||
| Q2 25 | 21.5% | 20.9% | ||
| Q1 25 | 20.9% | 20.3% | ||
| Q4 24 | 19.5% | 23.4% | ||
| Q3 24 | 22.2% | 21.1% | ||
| Q2 24 | 21.6% | 19.9% | ||
| Q1 24 | 19.3% | 20.4% |
净利率ALLEMEDP
| Q4 25 | 14.3% | 19.1% | ||
| Q3 25 | 17.6% | 16.8% | ||
| Q2 25 | 15.6% | 15.0% | ||
| Q1 25 | 15.7% | 20.5% | ||
| Q4 24 | 15.2% | 21.8% | ||
| Q3 24 | 18.0% | 18.1% | ||
| Q2 24 | 16.1% | 16.7% | ||
| Q1 24 | 13.8% | 20.1% |
每股收益（稀释后）ALLEMEDP
| Q4 25 | $1.70 | $4.65 | ||
| Q3 25 | $2.18 | $3.86 | ||
| Q2 25 | $1.85 | $3.10 | ||
| Q1 25 | $1.71 | $3.67 | ||
| Q4 24 | $1.65 | $3.67 | ||
| Q3 24 | $1.99 | $3.01 | ||
| Q2 24 | $1.77 | $2.75 | ||
| Q1 24 | $1.41 | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $356.2M | $497.0M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $2.1B | $459.1M |
| 总资产 | $5.2B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.96× | — |
8季度趋势，按日历期对齐
现金及短期投资ALLEMEDP
| Q4 25 | $356.2M | $497.0M | ||
| Q3 25 | $302.7M | $285.4M | ||
| Q2 25 | $656.8M | $46.3M | ||
| Q1 25 | $494.5M | $441.4M | ||
| Q4 24 | $503.8M | $669.4M | ||
| Q3 24 | $878.9M | $656.9M | ||
| Q2 24 | $747.5M | $510.9M | ||
| Q1 24 | $391.8M | $407.0M |
总债务ALLEMEDP
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.0B | — |
股东权益ALLEMEDP
| Q4 25 | $2.1B | $459.1M | ||
| Q3 25 | $1.9B | $293.6M | ||
| Q2 25 | $1.8B | $172.4M | ||
| Q1 25 | $1.6B | $593.6M | ||
| Q4 24 | $1.5B | $825.5M | ||
| Q3 24 | $1.6B | $881.4M | ||
| Q2 24 | $1.4B | $763.6M | ||
| Q1 24 | $1.4B | $671.5M |
总资产ALLEMEDP
| Q4 25 | $5.2B | $2.0B | ||
| Q3 25 | $5.2B | $1.8B | ||
| Q2 25 | $4.9B | $1.6B | ||
| Q1 25 | $4.6B | $1.9B | ||
| Q4 24 | $4.5B | $2.1B | ||
| Q3 24 | $5.0B | $2.1B | ||
| Q2 24 | $4.8B | $1.9B | ||
| Q1 24 | $4.3B | $1.8B |
负债/权益比ALLEMEDP
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 1.53× | — | ||
| Q2 24 | 1.69× | — | ||
| Q1 24 | 1.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $240.1M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $200.5M | $188.1M |
| 自由现金流率自由现金流/营收 | 19.4% | 26.6% |
| 资本支出强度资本支出/营收 | 3.8% | 0.6% |
| 现金转化率经营现金流/净利润 | 1.63× | 1.43× |
| 过去12个月自由现金流最近4个季度 | $685.7M | $681.9M |
8季度趋势，按日历期对齐
经营现金流ALLEMEDP
| Q4 25 | $240.1M | $192.7M | ||
| Q3 25 | $229.5M | $246.2M | ||
| Q2 25 | $209.7M | $148.5M | ||
| Q1 25 | $104.5M | $125.8M | ||
| Q4 24 | $219.0M | $190.7M | ||
| Q3 24 | $231.9M | $149.1M | ||
| Q2 24 | $173.0M | $116.4M | ||
| Q1 24 | $51.1M | $152.7M |
自由现金流ALLEMEDP
| Q4 25 | $200.5M | $188.1M | ||
| Q3 25 | $209.8M | $235.5M | ||
| Q2 25 | $192.0M | $142.4M | ||
| Q1 25 | $83.4M | $115.8M | ||
| Q4 24 | $194.9M | $183.0M | ||
| Q3 24 | $212.0M | $138.5M | ||
| Q2 24 | $152.1M | $103.5M | ||
| Q1 24 | $23.9M | $147.2M |
自由现金流率ALLEMEDP
| Q4 25 | 19.4% | 26.6% | ||
| Q3 25 | 19.6% | 35.7% | ||
| Q2 25 | 18.8% | 23.6% | ||
| Q1 25 | 8.9% | 20.7% | ||
| Q4 24 | 20.6% | 34.1% | ||
| Q3 24 | 21.9% | 26.0% | ||
| Q2 24 | 15.8% | 19.6% | ||
| Q1 24 | 2.7% | 28.8% |
资本支出强度ALLEMEDP
| Q4 25 | 3.8% | 0.6% | ||
| Q3 25 | 1.8% | 1.6% | ||
| Q2 25 | 1.7% | 1.0% | ||
| Q1 25 | 2.2% | 1.8% | ||
| Q4 24 | 2.5% | 1.4% | ||
| Q3 24 | 2.1% | 2.0% | ||
| Q2 24 | 2.2% | 2.4% | ||
| Q1 24 | 3.0% | 1.1% |
现金转化率ALLEMEDP
| Q4 25 | 1.63× | 1.43× | ||
| Q3 25 | 1.22× | 2.22× | ||
| Q2 25 | 1.31× | 1.65× | ||
| Q1 25 | 0.71× | 1.10× | ||
| Q4 24 | 1.52× | 1.63× | ||
| Q3 24 | 1.33× | 1.55× | ||
| Q2 24 | 1.11× | 1.32× | ||
| Q1 24 | 0.41× | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALLE
| Products | $750.2M | 73% |
| Allegion International | $237.7M | 23% |
| Services | $45.2M | 4% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
